logo-loader
CytoDyn

Full interview: CytoDyn reveals adjustment to its HIV monotherapy treatment in 'major' announcement

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive that the firm’s Senior Science Advisor Dr. Jonah Sacha, who leads the development of leronlimab (PRO 140) as a potential therapeutic for HIV Pre-Exposure Prophylaxis (PrEP) and HIV, has 'tweaked' the product in-vitro to produce a therapy that would be injected only once per month.

Dr Pourhassan says the move comes with the biotech competing against the big pharma majors like Gilead Sciences and ViiV Healthcare, which have each revealed progression in their own therapies to treat HIV.

Quick facts: CytoDyn

Price: $0.38

Market: OTCQB
Market Cap: $141.32 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

More on this story

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

7 hours, 30 minutes ago

2 min read